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The  treatment of latent tuberculosis is part of the strategy
to  eliminate tuberculosis (TB) in low incidence countries.1
Ten to 15 million people in the United States have latent TB,
and  about 300,000 Americans are treated for it each year.2
The currently recommended treatments for latent TB include
using  the drugs isoniazid, rifampin, and rifapentine plus
isoniazid.3,4
Rifampin was  discovered in 1957 and became a standard
treatment for tuberculosis years later. Although it is often
associated with drug interactions, rifampin is generally a
safe  drug. Its most common serious side effects are hepatic
and  immunologic. The immunologic side effects range from
ﬂu-like  syndrome to shock. Other immunologic side effects
include  thrombocytopenia, gastrointestinal symptoms, rash
and cutaneous leukocytoclastic vasculitis.5 However, to the
best  of our knowledge, the association between angioedema
and  rifampin has never been reported. We  observed a case of
angioedema  related to the use of rifampin.
A 62-year-old woman  was  a close contact of a patient
with active sputum positive TB. She had a positive Quantif-
eron  test and no evidence for active disease. She had never
taken  rifampin before. She had hypertension and hyperlipi-
demia  and took metoprolol 25 mg,  atorvastatin 20 mg,  calcium
and  vitamin D, and a multivitamin daily. She began rifampin
600  mg  daily. Four days later, she developed mild itching that
did  not respond to diphenhydramine. Twenty-three days later,
her lips and eyelid swelled and she developed a generalized
rash.  She was  admitted to the hospital for angioedema. No
abnormality  was  found in routine laboratory tests. She recov-
ered  2 days after stopping rifampin. Her latent tuberculosis
was  later treated with isoniazid.
In this patient, angioedema developed about a month
after starting rifampin and recovered soon after its discon-
tinuance. There was  no eosinophilia associated with the
reaction.  Possible rifampin-associated angioedema was  ques-
tioned previously, but data have not strongly supported it.6
The pathogenesis of rifampin-induced angioedema is not
clear.  It may  be a non-immunoglobulin E (IgE) mediated mech-
anism  with an imbalance in the arachidonic acid cascade,
increasing of leukotrienes or bradykinin-mediated.7 We alertreaders to this adverse effect of a widely prescribed drug to
avoid  serious outcomes. Rifampin-induced angioedema is a
life threatening side effect; therefore, rifampin should not be
readministered.
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